DBV Technologies DBVT Elevated to 'Hold' by StockNews.com as Institutional Interest Surges

Analysts at StockNews.com have updated their recommendation on DBV Technologies S.A. DBVT, a clinical-stage biopharmaceutical company committed to developing epicutaneous immunotherapy treatments. The firm has revised its rating from 'sell' to 'hold' for the DBVT stock in a research note distributed to investors. This change reflects a potential shift in market sentiment towards the company whose headquarters are located in Montrouge, France.

Brokerage Consensus on DBV Technologies

DBV Technologies has been the focus of several brokerage notes. While JMP Securities reaffirmed a 'market outperform' rating with a target price of $4.00, HC Wainwright maintained a 'buy' rating, setting a price goal of $10.00 for DBVT. On the other end, The Goldman Sachs Group reduced its price target from $1.30 to $1.00 and sustained a 'sell' determination. Overall, the consensus among market analysts categorizes DBV Technologies as a 'Hold,' with a mean target price pegged around $5.00.

Recent Performance and Market Position of DBVT

DBVT opened trade at $0.95 on the noted Friday, operating within a 52-week span that saw a low of $0.91 and a high of $2.37. The firm's market capitalization currently stands at $182.90 million, supported by a 50-day moving average price of $1.25 and a 200-day moving average of $1.57, despite a negative PE ratio of -1.70 and a beta of 1.19.

Institutional Movements in DBV Technologies

A growing interest from institutional investors has been observed in DBVT. BlackRock, Inc. BLK, an American multinational investment management corporation based in New York City, raised its holdings by 4.6%, resulting in ownership of 1,017,670 shares worth approximately $1,934,000. Landscape Capital Management and Point72 Asset Management are among the new entrants, with stakes valued at $94,000 and $5,914,000 respectively. Other participants like Citadel Advisors LLC and Optiver Holding B.V. have also made significant investments, indicating a bolstering confidence in DBVT's market potential.

DBV Technologies Company Highlights

DBVT is engaged in the crucial research and development phase for its primary candidate, Viaskin Peanut, an epicutaneous immunotherapy product designed for treating peanut allergies, which has completed Phase III trials. The company continues to advance its immunotherapy portfolio, including Viaskin Milk, targeting IgE mediated cow's milk protein allergy and eosinophilic esophagitis, currently in Phase I/II clinical trials.

DBVTechnologies, StockUpgrade, HoldRating, InstitutionalInvestors, BlackRock, ClinicalTrials, Immunotherapy, EquityResearch, MarketSentiment